Fábio Coelho

Dr. Fábio Coelho


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2022
Verified
Journal Article
Open access
PDF file
FCFábio Coelho
Fábio Coelho
LCLaura Colete Cunha
Laura Colete Cunha
SLSabrina Francesca Lisboa
Sabrina Francesca Lisboa
Different stressors can elicit neuroinflammatory responses modulated by innate immunity receptors, such as the family of Toll-like receptors (TLRs). The TLR4, a pattern recognition receptor (PRR), is involved in many diseases, such as inflammatory and central nervous system (CNS) diseases. Stress exposure can regulate the expression of PRRs, including TLR4, in the brain of animals, especially in the hippocampus and prefrontal cortex. Moreover, TLR4 modulates behavior and neuroinflammatory responses in the brain. In addition, to TLR4, the endocannabinoid (eCB) system plays a role in stress response and immunity, acting as a regulatory, stress-buffer system. This system is involved in many TLRs-mediated immune responses, such as microglia activation. Therefore, pharmacological approaches targeting the eCB system could modulate neuroinflammatory responses to stress by interfering with the TLR4 pathway. Although the connection between TLR4, stress, and neuroinflammation is well documented, almost no pre-clinical studies investigate the possible direct relationship between TLR4, behavior, stress, and the eCB system. Studies exploring the relationship between stress, neuroinflammation, TLR4, and the eCB system were searched using Pubmed, Web of Science, and Embase databases. Based on this search, this review is focused on the involvement of TLR4 receptors and signaling in neuroinflammation and the behavioral consequences of stress exposure. Moreover, evidence of the eCB system modulating TLR4-mediated responses was brought to the attention, pointing out a possible regulatory role of these responses by eCBs in behavior changes related to mood disorders.

1 December 2025 in Revista Ibero-Americana de Humanidades, Ciências e Educação
Verified
Journal Article
Closed access
ABAna Laura Castro Brito
Ana Laura Castro Brito
TMTaceli Kenia Fernandes Martins
Taceli Kenia Fernandes Martins
SSSilvana Oliveira Sarmento
Silvana Oliveira Sarmento
LSLucas Oliveira da Silva
Lucas Oliveira da Silva
FCFábio Coelho
Fábio Coelho
Este artigo buscou analisar os avanços, limitações e disputas profissionais que permeiam a prescrição farmacêutica no Brasil, considerando seus marcos regulatórios, desafios jurídicos e impactos para a prática clínica. Para isso, realizou-se uma Revisão Integrativa da Literatura, seguindo as recomendações do protocolo PRISMA. A busca foi conduzida nas bases SciELO, PubMed, LILACS (BVS) e Google Acadêmico, utilizando descritores em português e inglês. Foram incluídos artigos completos publicados entre 2015 e 2025 que abordassem a prescrição farmacêutica, sua regulamentação, efeitos clínicos e controvérsias profissionais. Após triagem de 624 registros, 27 estudos atenderam aos critérios e compuseram a análise qualitativa. Os resultados evidenciam que a prescrição farmacêutica contribui para o uso racional de medicamentos, melhora da adesão terapêutica, redução de eventos adversos e fortalecimento do cuidado clínico nas farmácias comunitárias. Contudo, persistem obstáculos importantes, como insuficiência de qualificação clínica entre profissionais, lacunas estruturais nos serviços, baixa adesão da população ao retorno clínico e disputas corporativas que influenciam políticas regulatórias. A suspensão judicial da Resolução CFF nº 586/2013 revelou fragilidades normativas e reforçou a necessidade de critérios rigorosos de certificação, como o Registro de Qualificação Especial (RQE). Conclui-se que o avanço da prescrição farmacêutica demanda governança regulatória, competência técnica certificada e integração multiprofissional para garantir segurança ao paciente e efetividade no cuidado.

9 October 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
EFEmily Christie Christie Maia Fonseca
Emily Christie Christie Maia Fonseca
LPLucas Villar Pedrosa da Silva Pantoja
Lucas Villar Pedrosa da Silva Pantoja
DCDaniele Luz De Campos
Daniele Luz De Campos
FCFábio Coelho
Fábio Coelho
BPBruno Gonçalves Pinheiro
Bruno Gonçalves Pinheiro
JMJosé Guilherme Soares Maia
José Guilherme Soares Maia
Background/Objectives: Neurological and psychiatric disorders share overlapping mechanisms, such as oxidative stress, neuroinflammation, and neurotransmitter imbalance. In this context, multitarget natural molecules have gained attention. 1-nitro-2-phenylethane (1N2PE), a major constituent of Aniba canelilla essential oil, is known for its antioxidant, anti-inflammatory, and anticholinesterase effects, yet its neuropharmacological profile remains poorly understood. Methods: This study integrated in silico predictions and in vivo behavioral assays to characterize 1N2PE. Results: Pharmacokinetic analyses indicated favorable drug-like properties, with high gastrointestinal absorption, blood–brain barrier penetration, and no P-gp substrate profile. Molecular docking and dynamics revealed stable interactions with dopamine transporter (DAT, ΔG = −26.26 kcal/mol), prostaglandin-H synthase-1 (PGHS-1, ΔG = −20.27 kcal/mol), serotonin transporter (SERT, ΔG = −18.20 kcal/mol), and acetylcholinesterase (AChE, ΔG = −16.58 kcal/mol). In vivo, using a scopolamine-induced impairment model, 1N2PE significantly improved spatial memory and cognition in the Morris water maze. Treated animals reduced the distance to the target zone by ~40% compared with scopolamine-only rats (p < 0.01), normalized latency during training, and exhibited 30% less immobility (p < 0.05), indicating antidepressant-like effects. Moreover, 1N2PE attenuated anxiety-like thigmotaxis, restoring exploratory patterns (p < 0.0001). Conclusions: Together, these findings highlight 1N2PE as a multitarget candidate for cognitive and psychiatric disorders, combining favorable pharmacokinetic properties with preclinical efficacy, warranting further biochemical and translational investigations.

17 March 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
STSarah Andrade Toledo
Sarah Andrade Toledo
LRLaryssa Danielle da Silva Reis
Laryssa Danielle da Silva Reis
BCBrenda Costa da Conceição
Brenda Costa da Conceição
LPLucas Villar Pedrosa da Silva Pantoja
Lucas Villar Pedrosa da Silva Pantoja
FCFábio Coelho
Fábio Coelho
Enéas Andrade Fontes-JuniorEnéas Andrade Fontes-Junior
Enéas Andrade Fontes-Junior
The Vatairea genus (Fabaceae family) is widespread in the Amazon rainforest. Some species of this genus are known for their ethnobotanical significance and biological potential. The present study explores the pharmacological and promising therapeutic activities, ethnobotanical profile, and phytochemical prospection of Vatairea sp., a monophyletic group of flowering plants, which includes economically and culturally important genera due to their diverse uses, including medicinal applications. V. lundellii, V. guianensis, V. erythrocarpa, V. fusca, V. heteroptera, V. paraensis, V. sericea, and V. macrocarpa are included in the Vatairea sp., also recognized for its high wood quality and potential medicinal properties. Studies show significant antibacterial activity in V. guianensis extracts against Gram-positive and Gram-negative bacteria, whereas V. macrocarpa lectin exhibits broad-spectrum antibacterial effects, including modulation of antibiotic resistance. Additionally, V. macrocarpa and V. guianensis have demonstrated antifungal properties, with compounds like Vatacarpan exhibiting potent activity against Candida sp. In vivo studies highlight the neurotoxic effects of V. macrocarpa lectin, suggesting a dual role in the central nervous system. Despite these findings, research on Vatairea’s toxicological aspects is limited, with only a few studies on V. macrocarpa and V. guianensis extracts indicating a need for further exploration of this genus’ pharmacological and therapeutic potential.